Specifically, significant clinical factors for OS were tumor size and clinical stage (P = 0.011 and 0.009, respectively), whereas tumor size (P = 0.003), clinical stage (P = 0.009), PR (P = 0.001) and Ki67 (P = 0.042) were significant factors for DFS in breast cancer. This evidence concerns the gene PGR and breast carcinoma.